Loading...
XSHG603963
Market cap87mUSD
Dec 23, Last price  
2.89CNY
1D
-4.93%
1Q
4.71%
IPO
-68.14%
Name

Dali Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603963 chart
P/E
—
P/S
7.28
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-0.81%
Rev. gr., 5y
-26.30%
Revenues
87m
-34.06%
285,267,963297,649,847338,686,426266,965,263275,764,813272,739,025401,483,012294,324,901213,583,457171,493,284132,344,03387,269,974
Net income
-20m
94,594,08892,031,892100,069,95662,292,68162,165,67544,452,48510,700,46513,505,4923,231,66600-20,031,372
CFO
-26m
100,745,768106,593,76895,854,270114,864,82988,682,70626,916,67178,115,4667,328,803010,509,2750-26,006,525
Dividend
Jun 23, 20210.046 CNY/sh
Earnings
May 16, 2025

Profile

Dali Pharmaceuticalco.,Ltd researches, develops, produces, and sells pharmaceutical products in China. It develops Chinese and Western medicine injection products of 20 varieties with 44 specifications of the injection drug approval number. The company's products include xingnaojing, shenmai, and astragalus injections, as well as leucocin A and citicoline injections. It also has 31 patents, including 11 invention patents, 16 utility models, and 3 design patents. The company was founded in 1996 and is headquartered in Dali, China.
URL
http://www.daliyaoye.cn/
IPO date
Sep 22, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
87,270
-34.06%
132,344
-22.83%
171,493
-19.71%
Cost of revenue
96,821
137,449
167,983
Unusual Expense (Income)
NOPBT
(9,551)
(5,105)
3,510
NOPBT Margin
2.05%
Operating Taxes
2,663
704
299
Tax Rate
8.51%
NOPAT
(12,214)
(5,809)
3,211
Net income
(20,031)
 
Dividends
(10,106)
Dividend yield
0.52%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
8,010
21,399
17,097
Long-term debt
15,681
27,157
41,798
Deferred revenue
346
434
522
Other long-term liabilities
1
1
Net debt
(197,304)
(288,184)
(446,988)
Cash flow
Cash from operating activities
(26,007)
10,509
CAPEX
(7,699)
Cash from investing activities
20,362
90,667
Cash from financing activities
(24,000)
16,150
FCF
(10,769)
46,385
(8,145)
Balance
Cash
220,932
273,072
313,102
Long term investments
63
63,668
192,781
Excess cash
216,632
330,123
497,309
Stockholders' equity
230,657
283,357
301,059
Invested Capital
187,699
157,796
169,925
ROIC
1.75%
ROCE
0.75%
EV
Common stock shares outstanding
222,571
219,700
219,700
Price
11.88
-9.04%
13.06
47.74%
8.84
13.33%
Market cap
2,644,141
-7.85%
2,869,282
47.74%
1,942,148
13.33%
EV
2,446,837
2,581,098
1,495,160
EBITDA
6,454
12,744
21,015
EV/EBITDA
379.13
202.53
71.15
Interest
1,724
1,078
247
Interest/NOPBT
7.05%